INTS

Business Context and Reporting Period

Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A late-stage clinical biotechnology company developing INT230-6, an intratumoral cancer treatment using the DfuseRx platform. The company has no product revenue and relies on equity financing.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Improvement: Net loss decreased by $0.4 million (7.5%) to $5.4 million for the six months ended June 30, 2026, compared to $5.9 million in the prior year period. This was driven primarily by a $0.7 million reduction in Research and Development (R&D) expenses.
• R&D Expenses: Total R&D expenses decreased to $3.0 million from $3.7 million. The decline was largely due to a $0.8 million reduction in costs for the INVINCIBLE-3 Phase 3 Sarcoma study, which was paused in March 2025 due to funding constraints. However, costs for this study increased in the most recent quarter as the company initiated plans to resume enrollment.
• Stock-Based Compensation: Decreased to $0.8 million from $1.1 million year-over-year, as no new stock-based compensation awards were granted in the first half of 2026.
• Capital Structure: The company executed a 1-for-25 reverse stock split in February 2026. As of June 30, 2026, there were 2,945,552 shares outstanding, compared to 1,046,657 shares (restated) as of June 30, 2025.
• Financing Activity: Net cash provided by financing activities dropped to $1.8 million from $4.1 million, reflecting a shift from large public offerings in 2025 to smaller At-The-Market (ATM) offerings in 2026.

Guidance, Outlook, and Risks

• Going Concern Warning: Management explicitly states there is "substantial doubt" about the company's ability to continue as a going concern. With $9.5 million in cash and no product revenue, the company expects to incur substantial losses for the foreseeable future and must raise additional capital to continue operations.
• Clinical Trial Status:
  • INVINCIBLE-3 (Phase 3 Sarcoma): Enrollment was paused in March 2025. In April 2026, the company initiated plans to resume enrollment in limited U.S. sites, with full enrollment expected to begin in Q3 2026 pending funding.
  • INVINCIBLE-4 (Phase 2 Breast Cancer): Enrollment was paused in September 2025 to revise dosing. A protocol amendment was approved in March 2026, and enrollment resumed in Q2 2026. The company targets completing enrollment by the end of 2027.
• Capital Needs: The company plans to finance operations through equity offerings (including an ATM agreement with $58.4 million remaining capacity) and convertible debt. Subsequent to June 30, 2026, the company raised an additional $1.3 million via the ATM agreement.
• Risks: Key risks include the inability to raise additional capital, delays in clinical trials, failure to obtain regulatory approval, and the impact of military actions in Russia and Israel on the company's patent portfolio.

Investor Verification Checklist

• Cash Runway: Verify the current cash burn rate against the $9.5 million cash balance to estimate the timeline before additional financing is critically required.
• Financing Capacity: Confirm the remaining capacity under the $60 million ATM agreement and the terms of any potential new debt or equity offerings.
• Clinical Resumption: Monitor the actual start date of patient enrollment for the INVINCIBLE-3 and INVINCIBLE-4 studies and the associated cost implications.
• Reverse Stock Split Impact: Review the impact of the 1-for-25 reverse stock split on share count, option exercise prices, and market liquidity.
• Patent Exposure: Assess the specific risks to the company's intellectual property in Russia and Israel due to ongoing military conflicts.